Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONCOFUCO is a dietary supplement and functional ingredient developed by Hi-Q Marine Biotech International, specifically formulated for cancer supportive care. Its primary active component is OliFuco®, a proprietary low molecular weight fucoidan (oligofucoidan) extracted from the brown seaweed *Laminaria japonica*. Each 550 mg capsule contains high-purity fucoidan designed to serve as an adjunctive therapy for cancer patients. The product is intended to modulate the immune system, mitigate the side effects of chemotherapy and radiotherapy, and address cancer-related cachexia. Clinical research, including a double-blind randomized controlled trial in metastatic colorectal cancer patients, supports its use in improving patient outcomes and quality of life. ONCOFUCO has been available in the Taiwanese market for over 14 years and is utilized in hospitals and clinics, holding the Symbol of National Quality (SNQ) certification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ONCOFUCO.